Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qingxia Fan

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
British Journal of Cancer|October 19, 2022
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trialShukui Qin, Jin Li, Haijun Zhong, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2023
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phasesYe Guo, Weijie Zhang, Jieer Ying, et al.
Cancer Communications (London, England)|April 4, 2019
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trialJing Huang, Binghe Xu, Ying Liu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 1, 2018
A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancerZhihao Lu, Xiaotian Zhang, Wei Liu, et al.
BMC Gastroenterology|October 24, 2021
Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b studyRongrui Liu, Lianke Liu, Chuanhua Zhao, et al.
Journal for Immunotherapy of Cancer|January 17, 2025
Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trialZhichao Tan, Yan Wu, Zhengfu Fan, et al.
BMC Cancer|February 7, 2023
Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II studyChuanliang Cui, Yu Chen, Zhiguo Luo, et al.
JAMA|February 24, 2025
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical TrialXiaotian Zhang, Jufeng Wang, Gang Wang, et al.
The Oncologist|January 25, 2014
The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinomaJifang Gong, Bing Hu, Xiaotian Zhang, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 4, 2021
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumorsYingying Xu, Yakun Wang, Jifang Gong, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
British Journal of Cancer|October 19, 2022
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trialShukui Qin, Jin Li, Haijun Zhong, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2023
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phasesYe Guo, Weijie Zhang, Jieer Ying, et al.
Cancer Communications (London, England)|April 4, 2019
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trialJing Huang, Binghe Xu, Ying Liu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 1, 2018
A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancerZhihao Lu, Xiaotian Zhang, Wei Liu, et al.
BMC Gastroenterology|October 24, 2021
Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b studyRongrui Liu, Lianke Liu, Chuanhua Zhao, et al.
Journal for Immunotherapy of Cancer|January 17, 2025
Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trialZhichao Tan, Yan Wu, Zhengfu Fan, et al.
BMC Cancer|February 7, 2023
Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II studyChuanliang Cui, Yu Chen, Zhiguo Luo, et al.
JAMA|February 24, 2025
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical TrialXiaotian Zhang, Jufeng Wang, Gang Wang, et al.
The Oncologist|January 25, 2014
The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinomaJifang Gong, Bing Hu, Xiaotian Zhang, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 4, 2021
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumorsYingying Xu, Yakun Wang, Jifang Gong, et al.
Pageof 11